Latest Strategic Collaborations News

Great Boulder Resources is set to acquire Westgold’s Peak Hill Gold Project for $25 million cash, a 19.9% stake, and a 1% royalty, significantly boosting its gold resources and advancing near-term production plans.

Eagers Automotive has finalized its majority acquisition of CanadaOne Auto, positioning itself among the world’s largest automotive retail groups with combined pro-forma revenue nearing A$19 billion.

Noxopharm’s SOF-16 active ingredient demonstrated potent anti-inflammatory activity in patient-derived samples of systemic lupus erythematosus and rheumatoid arthritis, advancing its Sofra™ platform beyond topical applications.

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

Osmond Resources is progressing its Orión EU Critical Minerals Project with promising drilling results, positive mineral processing testwork, and a new partnership targeting rare earth carbonate production in Spain.

PT ANTAM TBK sustained strong operational performance in Q1 2026 with robust gold and nickel sales amid favourable market trends, while pushing forward strategic mineral downstreaming projects including Indonesia's integrated battery ecosystem.

HighCom Technology secures a nearly A$10 million contract from the Australian Defence for counter small uncrewed aerial systems, marking its first major C-UAS order and reinforcing its defence sector presence.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Aurora Labs has made significant strides in commercial propulsion delivery and deepened its partnership with European defence giant MBDA, while scaling manufacturing capabilities and reinforcing its Board with defence expertise.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.